Cancer Vaccine Market Expected To Surpass USD 15 Billion As Per Recent Report Published By Kuick Research.
Cancer Vaccine Market Expected To Surpass USD 15 Billion As Per Recent Report Published By Kuick Research
Global Cancer Vaccine Market & Clinical Trials Outlook 2028 Highlights:
- Global and Regional Market Size Insight 2022 Till 2028
- Cancer Vaccine Market Insight & Forecast By 10 Countries 2022 Till 2028
- Cancer Vaccine Market Insight & Forecast By 10 Different Cancers 2022 Till 2028
- Approved Cancer Vaccines Patent, Price, & Dosage Analysis
- Insight On More Than 350 Cancer Vaccines in Clinical Trials
- Cancer Vaccines Trials Insight By Company, Country and Indication
- Insight On More Than 20 Cancer Vaccines Commercially Available In Market
Download Report: https://www.kuickresearch.com/report-global-cancer-vaccine-market-size
Cancer vaccines are biological response modifiers which work by stimulating the immune system against targeted cancer cells. Currently, several prophylactic HPV virus-like particle-based vaccines including Cervarix, Gardasil, and Gardasil 9 have been licensed to date, and they have all shown high efficacy and reliable safety profiles. In addition to this, Provenge for the management of prostate cancer, Riavax for the management of pancreatic cancer, and CimaVax as well Vaxira for the management of non-small cell lung cancer have also gained marketing authorization. The introduction of vaccines has opened new avenues for the prevention as well as therapeutic management of cancer.
Currently, HPV cancer vaccines are holding the dominant share in the global market which is mainly attributed to new product launch, extended approval to approved vaccines, as well as rising initiatives by government. Recently in March 2022, Japan’s health ministry resumed recommending that Japanese girls aged 12 to 16 years to get vaccinated against HPV. Further, China NMPA has approved two dose vaccine schedule for Cervarix in girls aged between 9 to 14 years for the prevention of cervical cancer, cervical intraepithelial neoplasia, and adenocarcinoma in situ casually related to HPV types 16 and 18. With this approval, Cervarix is first imported two dose HPV vaccine in mainland China.
Despite huge success of HPV vaccines, the pipeline is highly crowded which aims to target other variants of HPV. For instance, Transgene has developed TG4001 which is investigational therapeutic vaccine based on non-propagative highly attenuated Vaccinia vector (MVA), which is engineered to express HPV16 antigens (E6 and E7) and an adjuvant (IL-2). The novel vaccine is designed to have two prolonged antiviral approach including to alert the immune system specifically to cells presenting the HPV16 E6 and E7 antigens, that can be found in HPV16-related tumors, and to further stimulate the infection-clearing activity of the immune system through interleukin 2 (IL-2). Another, Inovio has developed VGX-3100 which is an investigational immunotherapy consisting of DNA plasmids targeting E6 and E7 proteins of HPV 16 and 18.
Although HPV vaccines currently holds maximum share in the market, the trend is expected to change in coming years. It is believed that therapeutic cancer vaccines will enter the market in next 3-5 years which will show huge adoption rate among individuals wing to their enhanced efficacy and targeted nature. Recently, group of researchers at Cleveland Clinic have identified a protein called alpha-lactalbumin that is present in healthy breast tissue only when a woman is lactating and disappears when she stops nursing her child. Alpha-lactalbumin is never present on any other cell in the body. However, the protein is expressed on triple negative breast cancer cell lines. Recently in 2022, US FDA has granted approval to investigational new drug application to the vaccine which permits Cleveland Clinic and partner Anixa Biosciences to initiate the study. The phase-I trial is designed to determine the maximum tolerated dose of the vaccine in patients with early-stage triple-negative breast cancer and to characterize and optimize the body’s immune response.
Although several factors drive the growth of cancer vaccine market, the major challenge to effective cancer vaccine development is targeting of tumor antigens that may have low immunogenicity in the tumor microenvironment or may mutate to evade the immune response. In addition, several cancer vaccines failed at late stage clinical trials which also restrict the investment in this sector. To overcome these challenges, research studies are now focusing on utilizing cancer vaccines in combination with other cancer targeting regimes to enhance its efficacy and immunogenicity. The presence of large number of ongoing clinical trials and their promising response suggests huge potential of vaccines in global cancer therapeutics market. As per our report findings, the global cancer vaccine market is expected to surpass US$ 15 Billion by 2028.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366